AAPG insider trading
NasdaqGM HealthcareASCENTAGE PHARMA GROUP INTERNATIONAL — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Company website: www.ascentage.cn
AAPG insider activity at a glance
FilingIQ has scored 25 insider transactions for AAPG since Apr 20, 2026. The most recent filing in our index is dated May 21, 2026.
Across the full history, 0 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AAPG?
- FilingIQ tracks 25 Form 4 insider transactions for AAPG (ASCENTAGE PHARMA GROUP INTERNATIONAL), covering filings from Apr 20, 2026 onwards. 25 of those were filed in the last 90 days.
- Are AAPG insiders net buyers or net sellers?
- Across the full Form 4 history for AAPG, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AAPG insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is AAPG in?
- ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.45B.
Methodology & sources
Every AAPG insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.